Primary pulmonary lymphoproliferative neoplasms

Tang, Victoria K.; Vijhani, Praveen; Cherian, Sujith V.; Ambelil, Manju; Estrada‐Y‐Martin, Rosa M.

doi:10.4103/lungindia.lungindia_381_17

Cited by 16 publications

(8 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment includes surgical resection on localized or peripherally located lesions [ 40 , 75 ], and long watchful waiting, radiotherapy, or single-agent chemotherapy in non-resectable cases, depending on patient comorbidities [ 40 , 76 , 77 , 78 ]. Radiotherapy seems to be associated with lower morbidity in comparison with surgery [ 37 , 78 ].…”

Section: Primary Pulmonary Marginal Zone Lymphoma Of Mucosa-associmentioning

confidence: 99%

Primary Pulmonary B-Cell Lymphoma: A Review and Update

Sanguedolce

Zanelli

Zizzo

et al. 2021

Cancers

View full text Add to dashboard Cite

Primary pulmonary B-cell lymphomas (PP-BCLs) comprise a group of extranodal non-Hodgkin lymphomas of B-cell origin, which primarily affect the lung without evidence of extrapulmonary disease at the time of diagnosis and up to 3 months afterwards. Primary lymphoid proliferations of the lung are most often of B-cell lineage, and include three major entities with different clinical, morphological, and molecular features: primary pulmonary marginal zone lymphoma of mucosa-associated lymphoid tissue (PP-MZL, or MALT lymphoma), primary pulmonary diffuse large B cell lymphoma (PP-DLBCL), and lymphomatoid granulomatosis (LYG). Less common entities include primary effusion B-cell lymphoma (PEL) and intravascular large B cell lymphoma (IVLBCL). A proper workup requires a multidisciplinary approach, including radiologists, pneumologists, thoracic surgeons, pathologists, hemato-oncologists, and radiation oncologists, in order to achieve a correct diagnosis and risk assessment. Aim of this review is to analyze and outline the clinical and pathological features of the most frequent PP-BCLs, and to critically analyze the major issues in their diagnosis and management.

show abstract

Section: Primary Pulmonary Marginal Zone Lymphoma Of Mucosa-associmentioning

confidence: 99%

Primary Pulmonary B-Cell Lymphoma: A Review and Update

Sanguedolce

Zanelli

Zizzo

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Notably, lymph nodes are uninvolved at initial presentation 1 and in certain instances, lung involvement may be absent. 78 EBV+ LG lesions are characterized by the presence of sporadic large, atypical B cells 79 amidst a background of abundant reactive CD4+ Helper T cells, plasma cells, macrophages, and a variable number of giant atypical lymphoid cells resembling immunoblasts, plasmablasts, or Reed-Sternberg cells. The lesions frequently center on and exhibit damage of small blood vessels but they lack well-formed granulomas.…”

Section: Epstein-barrmentioning

confidence: 99%

Ebv-Related Lymphoproliferative Diseases: A Review in Light of New Classifications

Tralongo,

Bakacs,

Larocca

2024

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is a prevalent virus that can be detected in the vast majority of the population. Most people are asymptomatic and remain chronically infected throughout their lifetimes. However, in some populations, EBV has been linked to a variety of B-cell lymphoproliferative disorders (LPDs), such as Burkitt lymphoma, classic Hodgkin lymphoma, and other LPDs. T-cell LPDs have been linked to EBV in part of peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphomas, extranodal nasal natural killer/T-cell lymphomas, and other uncommon histotypes. This article summarizes the current evidence for EBV-associated LPDs in the light of the upcoming World Health Organization classification and the 2022 ICC classification. Keywords: Epstein Barr Virus: EBV, Lymphoma; Lymphoproliferative Diseases.WHO Classification.

show abstract

“…The patients often have no history of extranodal lymphoma at the time of the initial diagnosis or within the following 3 months. 1,2 Primary pulmonary lymphoma is a rare tumor, accounting for only 0.4% of all malignant lymphomas and 3% to 4% of extranodal lymphomas. 3,4 Pulmonary mucosa-associated lymphoid tissue lymphoma (MALToma), the most common PPL type (70-90%), originates from the MALT B progenitor cells and is also known as extranodal marginal zone B-cell lymphoma.…”

mentioning

confidence: 99%

“…Primary pulmonary lymphoma (PPL) is an extranodal lymphoma originating in the lung tissues, often involving the lung parenchyma and/or bronchi. The patients often have no history of extranodal lymphoma at the time of the initial diagnosis or within the following 3 months 1,2 . Primary pulmonary lymphoma is a rare tumor, accounting for only 0.4% of all malignant lymphomas and 3% to 4% of extranodal lymphomas 3,4 .…”

mentioning

confidence: 99%

With the Increasing Health Awareness: Clinical and Computed Tomography Findings in Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Lymphoma

Xie

Dong

Zhang

et al. 2022

J Comput Assist Tomogr

View full text Add to dashboard Cite

Objective:The objective of this study is to investigate the clinical manifestations, computed tomography (CT) findings, and prognosis of primary pulmonary mucosa-associated lymphoid tissue lymphoma (MALToma) with the improved health awareness nowadays.Methods: Clinical data and CT images of patients with pathologically confirmed MALToma from October 2012 to October 2021 were retrospectively analyzed.Results: Eighteen MALToma patients were included in the study (8 men and 10 women; mean age, 56.17 years; range, 33-73 years). Six men had a long-term history of smoking (>20 years). One patient had an autoimmune disease (Sjögren syndrome). Eight patients (44.44%) were asymptomatic, and 10 (55.56%) had mild chest or systemic symptoms. Most lesions (88.89%) were subpleural or located along the bronchovascular tree. According to the CT characteristics, the lesions were divided into 4 groups: nodular type (n = 8; 44.44%, including 5 solid nodules and 3 ground-glass nodules), mass type (n = 4, 22.22%), patch or consolidate type (n = 5, 27.78%), and mixed type (n = 1, 5.56%). Air bronchogram (11/18, 61.11%) and angiogram sign (8/16, 50%) were the most frequent CT findings and may help differential diagnosis. The patients were misdiagnosed with lung cancer (n = 11, 61.11%), inflammatory or chronic inflammatory disease (n = 4, 22.22%), bronchiectasis accompanied by infection (n = 1, 5.56%), diffuse interstitial lung disease (n = 1, 5.56%), and granuloma or tuberculosis (n = 1, 5.56%). The prognosis of all patients was favorable; 1 patient was lost to follow-up.Conclusions: Nowadays, patients with MALToma are usually asymptomatic or paucisymptomatic. Nodular lesions, including ground-glass nodules, are the most common presentation. Mucosa-associated lymphoid tissue lymphoma is most likely misdiagnosed as lung cancer. Lesions located in the subpleural areas or along the bronchovascular tree and presenting with an air bronchogram or angiogram sign could indicate a MALToma diagnosis.

show abstract

Primary pulmonary lymphoproliferative neoplasms

Cited by 16 publications

References 64 publications

Primary Pulmonary B-Cell Lymphoma: A Review and Update

Primary Pulmonary B-Cell Lymphoma: A Review and Update

Ebv-Related Lymphoproliferative Diseases: A Review in Light of New Classifications

With the Increasing Health Awareness: Clinical and Computed Tomography Findings in Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Lymphoma

Contact Info

Product

Resources

About